A novel thinking
DDR axis refines the classification of ccRCC with distinctive prognosis, multi omics landscape and management strategy
Bibliographic Data
| ID | 22078829 |
|---|---|
| Authors | Aimin Jiang (0000-0002-9563-983X, Second Military Medical University), Jiaao Song (Second Military Medical University), Xiao Fang (0000-0001-6142-7313, Second Military Medical University), Yu Fang (0000-0002-2810-806X, Second Military Medical University), Zheng Wang (0000-0003-0758-2202, Second Military Medical University), Bing Liu (0000-0003-2874-2746, Second Military Medical University), Zhenjie Wu (0000-0002-6487-5207, Second Military Medical University), Le Qu (0000-0001-9499-4277, Nanjing General Hospital of Nanjing Military Command, corresponding author), Peng Luo (0000-0002-3680-8509, Zhujiang Hospital, corresponding author), Linhui Wang (0000-0002-4056-0462, Second Military Medical University, corresponding author) |
| Year | 2022 |
| Volume | 10 |
| Pages | 1029509-1029509 |
| Publication date | 2022-11-21 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2296-2565 • E-ISSN: 2296-2565 |
| Publisher | Frontiers Media SA (PUBLISHER • CH) |
| DOI | 10.3389/fpubh.2022.1029509 |
| PMID | 36478716 |
| OpenAlex | W4309737614 |
| Language | EN |
| References cited | 76 |
Background: DNA damage response and repair (DDR) related signatures play an important role in maintaining genome stability and other biological processes. It also affects the occurrence, development, and treatment of cancer. However, in renal cell carcinoma (RCC), especially clear cell renal carcinoma (ccRCC), the potential association between DDR-related signatures and tumor heterogeneity and tumor microenvironment (TME) remains unclear. Methods: Utilizing unsupervised clustering algorithm, we divided RCC into two subgroups, DCS1 and DCS2, according to the differences in DDR gene expression, and compared the characteristics of the two subgroups through multiple dimensions. Results: Compared with DCS1, DCS2 patients have higher clinical stage/grade and worse prognosis, which may be related to active metabolic status and immunosuppression status. At the same time, the high mutation rate in DCS2 may also be an important reason for the prognosis. We also analyzed the sensitivity of the two subgroups to different therapeutic agents and established a subtypes' biomarkers-based prognostic system with good validation results to provide ideas for clinical diagnosis and treatment. Finally, we identified a pivotal role for DDX1 in the DDR gene set, which may serve as a future therapeutic target. Conclusion: This study showed that DDR has an important impact on the development and treatment of RCC. DCS2 subtypes have a poor prognosis, and more personalized treatment and follow-up programs may be needed. The assessment of DDR gene mutations in patients may be helpful for clinical decision-making. DDX1 may be one of the effective targets for RCC treatment in the future
Bioinformatics · Biology · Computational biology · Data science · Omics · Cancer Genomics and Diagnostics · Computer Science · Ferroptosis and cancer prognosis · Medicine · Renal cell carcinoma treatment
| Highly cited | No |
|---|